Literature DB >> 16353134

Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53.

Bente A Talseth1, Cliff Meldrum, Janina Suchy, Grzegroz Kurzawski, Jan Lubinski, Rodney J Scott.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited cancer syndrome associated with germline mutations in DNA mismatch repair (MMR) genes. Recently a polymorphism at codon 72 (R72P) in the tumour suppressor gene TP53 has been implicated in the age of disease onset in HNPCC. In this report we have studied a large cohort of HNPCC patients to assess the impact of this polymorphism on disease expression and age of diagnosis of colorectal cancer (CRC). DNA samples from 218 HNPCC mutation positive patients from Australia and Poland were genotyped for the arginine to proline change at codon 72 in the TP53 gene. The association between the polymorphism and disease characteristics (mutation status, disease expression and age of diagnosis of CRC) was tested using Pearson's Chi-square and Kaplan-Meier survival analysis. Our study of Australian and Polish HNPCC patients does not provide evidence for an association between the Arg/Pro (GC) genotype of the R72P polymorphism and age of diagnosis of CRC. The R72P polymorphism was examined in HNPCC patients and found to be not associated with disease development in either the Australian or Polish populations. When gene mutation status (hMLH1 or hMSH2) was included in the analysis some evidence of an affect was observed. The genotyping revealed in the Australian population that the R72P polymorphism was under-represented in the hMSH2 group whereas it was over-represented in the Polish hMSH2 group. A similar trend was observed for hMLH1 in both groups but was not significant. Age of diagnosis of CRC in HNPCC patients is therefore more complex than that predicted by the R72P TP53 polymorphism alone, suggesting an inter-relationship with other genetic and/or environmental factors. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353134     DOI: 10.1002/ijc.21661

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

2.  Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Ken Kawamoto; Nobuyuki Kikuno; Yutaka Suehiro; Naoko Okayama; Yuichiro Tanaka; Rajvir Dahiya
Journal:  J Urol       Date:  2008-03-20       Impact factor: 7.450

3.  Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome.

Authors:  Jinyun Chen; Carol J Etzel; Christopher I Amos; Qing Zhang; Nancy Viscofsky; Noralane M Lindor; Patrick M Lynch; Marsha L Frazier
Journal:  Cancer Causes Control       Date:  2009-08-19       Impact factor: 2.506

4.  TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.

Authors:  Abram Bunya Kamiza; Ling-Ling Hsieh; Reiping Tang; Huei-Tzu Chien; Chih-Hsiung Lai; Li-Ling Chiu; Tsai-Ping Lo; Kuan-Yi Hung; Jeng-Fu You; Wen-Chang Wang; Chao A Hsiung; Chih-Ching Yeh
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Youhong Jiang
Journal:  Oncotarget       Date:  2017-01-03

6.  The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Mark McEvoy; John Attia; Michael Gilbert; Ute Hamann; Rodney J Scott
Journal:  BMC Cancer       Date:  2008-09-29       Impact factor: 4.430

7.  Genetic variants in MUTYH are not associated with endometrial cancer risk.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2009-01-26       Impact factor: 2.857

Review 8.  Genetic modifiers of cancer risk in Lynch syndrome: a review.

Authors:  Bente A Talseth-Palmer; Juul T Wijnen; Desma M Grice; Rodney J Scott
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.